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Background: Although many of the factors and molecules closely associated with non-alcoholic steatohepatitis (NASH)
have been reported, the role of inducible nitric oxide synthase (iNOS)-derived nitric oxide (NO) on the progression of
NASH remains unclear. We therefore investigated the role of iNOS-derived NO in NASH pathogenesis with a long-term
follow-up study using systemic iNOS-knockout mice under high-fat diet (HFD) conditions.
Methods: iNOS-knockout and wild-type mice were fed a basal or HFD for 10 or 48 weeks. Lipid accumulation, fibrosis,
and inflammation were evaluated, and various factors and molecules closely associated with NASH were analyzed.
Results: Marked fibrosis and inflammation (indicators of NASH) were observed in the livers of iNOS-knockout mice
compared to wild-type mice after 48 weeks of a HFD; however, lipid accumulation in iNOS-knockout mice livers
was less than in the wild-type. Increased expressions of various cytokines that are transcriptionally controlled by
NF-kB in iNOS-deficient mice livers were observed during HFD conditions.
Conclusions: iNOS-derived NO may play a protective role against the progression to NASH during an HFD by
preventing fibrosis and inflammation, which are mediated by NF-kB activation in Kupffer cells. A lack of
iNOS-derived NO accelerates progression to NASH without excessive lipid accumulation.
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Non-alcoholic fatty liver disease (NAFLD) is the most
common liver disease, associated with systemic insulin re-
sistance (IR) and chronic liver inflammation, which in-
cludes non-alcoholic fatty liver (NAFL) and non-alcoholic
steatohepatitis (NASH). NAFL represents the first phase
of NASH, which is characterized by steatosis, and can
then develop into fatty liver disease with associated in-
flammation [1]. Although NASH is thought to lead to liver
fibrosis, cirrhosis and hepatocellular carcinoma, resulting
in increased morbidity and mortality, the pathogenesis
of NASH—such as the progression of hepatic NAFL to
NASH—remains unclear.* Correspondence: nakajima-tky@umin.ac.jp
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unless otherwise stated.We have previously reported that several potential
mechanisms are involved in the pathogenesis of NASH
[2-4]. Namely, we clearly showed that decrease in very
low-density lipoprotein (VLDL) synthesis caused lipid
accumulation in liver [2,3] and that leptin-mediated
CD14 up-regulation aggravated inflammation of liver
[4]. However, other factors associated with NASH pro-
gression remain to be determined.
Nitric oxide (NO) plays an important role in liver dis-
ease associated with IR and inflammation, and it has
been reported that chronic and systemic deficiency of in-
ducible nitric oxide synthase (iNOS) ameliorated high
fat diet (HFD)-induced whole-body IR [5-7]. Therefore,
iNOS is considered to be a target for the prevention of
fat accumulation in the liver, such as is associated with
NAFL. However, in liver inflammation and fibrosis, NO
is thought to have a protective effect against variousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tains the hepatic microcirculation [8,9], and inhibition of
NO generation leads to increased hepatic damage [10,11].
In the pathogenesis of NAFLD/NASH, the role of NO
is debatable: while the NO-AMP-activated protein kin-
ase (AMPK)-peroxisome proliferator-activated receptor
α (PPARα) signaling pathway is crucial for the control
of hepatic fatty acid oxidation [12], the excess production
of NO content, which leads to nitrosative stress, is corre-
lated with the severity of NAFLD [13]. Because of the
conflicting effects of NO on the liver, the exact roles of
iNOS and generated NO in the pathogenesis of NASH
has not yet been elucidated.
In this study, we investigated the role of iNOS-derived
NO in the pathogenesis of NASH in a long-term follow-
up study using systemic iNOS-knockout mice under HFD
conditions.
Methods
Animal treatment and procedures
We purchased a C57BL/6 J backcrossed C57BL/6 J-
Nos2tm1Lau colony from Jackson Labs (Bar Harbor, ME
04609, USA) to create male congenic wild-type (iNOS+/+)
and iNOS knockout (iNOS−/−) mice. Mice were allowed
free access to food and tap water throughout the
acclimatization and experimental periods.
From 6 weeks of age, each strain of mice were fed a
basal diet (BD) or a HFD. Forty-eight mice were dividing
into 4 groups: [1] iNOS+/+/BD; [2] iNOS−/−/BD; [3]
iNOS+/+/HFD; and [4] iNOS−/−/HFD. Two experimen-
tal periods of 10 and 48 weeks were examined using 6
mice from each group for each period. A HFD was admin-
istered using high-fat diet 32 containing 20% protein, 60%
fat, and 20% carbohydrate in powdered form from Japan
CLEA (Tokyo, Japan) and a BD containing 22% protein,
6% fat, and 47% carbohydrate was administered using MF
from Oriental Yeast Co., Ltd. (Tokyo, Japan). The precise
contents of these feeds were as previously described
[2]. All animals were treated humanely according to the
guidelines from the National Institutes of Health and
the AERI-BBRI Animal Care and Use Committee. Animal
protocols were approved by the Yokohama City University
Medical School guidelines for the care and use of labora-
tory animals.
Measurement of plasma and serum biochemical markers
Serum alanine aminotransferase (ALT) was measured
using Spotchem SP-4410 (Arklay Co., Kyoto, Japan). Total
serum cholesterol, triacylglycerol (TG) and plasma lipo-
protein levels were analyzed by an online dual-enzymatic
method for simultaneous quantification of cholesterol and
TG by high-performance liquid chromatography accord-
ing to a procedure previously described [2,14,15]. Fasting
plasma glucose, serum levels of fasting insulin, leptin,adiponectin and non-esterified fatty acid (NEFA) were
determined using a Glutest Pro kit (Sanwa Kagaku Ken-
kyusyo Co., Nagoya, Japan), an Ultra Sensitive Insulin
ELISA kit (Biochemical Research Laboratory, Morinaga
Milk Industry Co., Tokyo, Japan), an ELISA Mouse Leptin
kit (Biochemical Research Laboratory, Morinaga Milk
Industry Co., Tokyo, Japan), a Mouse/Rat Adiponectin
ELISA kit (Otsuka Pharmaceutical Co., Tokyo, Japan),
NEFA C-Test kit (Wako Pure Chemical Industries Co.,
Osaka, Japan), respectively. Blood IR was estimated using
the homeostasis model assessment of IR (HOMA-IR)
derived from the following equation: IR = fasting plasma glu-
cose level mg/dl × fasting serum insulin level ng/ml /22.5.
Insulin tolerance test (ITT)
Mice fed freely before being fasted for the study. They
were intraperitoneally challenged with 0.75 mU/g body
weight human insulin (Novolin R; Novo Nordisk, Denmark).
Blood samples were collected to measure glucose levels
at 0, 20, 40, 60, 80, 100 and 120 minutes after the insulin
injection [16].
Liver histopathological and immunohistochemical
evaluations
Liver samples were excised and embedded in Tissue-Tek
OCT compound (Sakura Finetek USA Inc, Torrance, CA,
USA) and paraffin for histological analysis. Formalin-fixed
and paraffin-embedded sections were processed rou-
tinely with hematoxylin and eosin (H&E) and Masson’s
trichrome staining. For evaluation of fat deposition, the
OCT-embedded samples were stained with oil-red O.
For quantification of liver collagen content, 50 fields were
microscopically examined at a 40× magnification using
a grid of 0.0625 mm2 with 100 points in Masson’s
trichrome-stained preparations. The samples were also
stained with monoclonal anti-actin, α-smooth muscle
antibodies (α-SMA) (Sigma-Aldrich, St Louis, MO, USA)
and phospho-nuclear factor kappa B (NF-kB) antibodies
(Cell Signaling Technology Japan, K.K., Tokyo, Japan).
Immunofluorescence was performed using 7-μm cryostat
liver sections. The sections were incubated with primary
antibodies and stained with Alexa Fluoro-conjugated
secondary antibodies (Cell Signaling Technology, Inc,
Japan). The primary antibodies used were phospho-nuclear
factor kappa B (NF-kB) antibodies (Cell Signaling Technol-
ogy Japan, K.K., Tokyo, Japan), F4/80 (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA, USA), and desmin antibodies
(Wako Pure Chemical Industries Co., Osaka, Japan) [4].
Liver histology and scoring systems
All histopathological findings were scored by the same
pathologists (Y.N. and S.M.), who were unaware of the
treatment that the animals had received. The histological
features were grouped into 3 broad categories: steatosis;
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for use with the NAFLD activity score (NAS) [17]. The
system of evaluation, which has previously been de-
scribed [18], is detailed in Table 1.
Measurement of liver triglyceride and fatty acid content
Liver samples were homogenized in 50 mM Tris/HCl
buffer, pH 7.4, containing 150 mM NaCl, 1 mM EDTA
and 1 mM PMSF. TG levels were analyzed enzymatically
using a diagnostic kit (Infinity™, Thermo DMA, Arlington,
TX, USA). Liver NEFA levels were determined by an acyl
CoA synthetase and acyl CoA oxidase enzyme method
with a commercial kit (NEFA C-Test; Wako Pure Chem-
ical Industries, Co., Osaka, Japan), after a chloroform/
methanol extraction according to the method described
by Folch et al. [19].
Liver NO assay
NO concentrations in the liver were determined using a
nitrate/nitrite colorimetric assay kit (Cayman Chemical,
Ann Arbor, Michigan 48108, USA). This assay is based on
the enzymatic conversion of nitrate to nitrite by nitrate
reductase. We constructed a standard curve using NO
standards [20].
Liver microsomal triglyceride transfer protein (MTP)
activity assay
MTP activity was measured using an MTP assay kit
(Roar Biochemical, New York, NY, USA) according to a
previously described method [21,22].
Quantification of gene expressions by real-time RT-PCR
Total RNA was isolated from the samples using an
RNeasy Mini kit (Qiagen GmbH., Hilden, Germany, Cat
NO. 74126), and reverse transcription to produce cDNA
using a TaqMan Gold RT-PCR Kit (Applied Biosystems,Table 1 Primer sequences used for real-time PCR analysis












CollagenI GAGCGGAGAGTACTGGATCG GTTCGGGCTGATGTACCAGTFoster City, CA, USA), were performed according
to the manufacturer’s instructions as previously de-
scribed [2].
Hepatic mRNA levels of several markers, as well as of
the housekeeping gene, β-actin, in the liver tissue were
determined using fluorescence-based real-time RT-PCR
on an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Real-time
RT-PCR was performed using the TaqMan and Power
SYBR® Green PCR Master Mix reagent, according to
the manufacturer’s instructions (Applied Biosystems, Foster
City, CA, USA). Values were normalized to the expression
level of the endogenous control, β-actin. The gene expres-
sion ratio was determined using data from WB mice as
the control group. The Probe and primer pair specific
for β-actin and MTP was purchased from Applied Bio-
systems. Primer sequences are listed in Table 1.Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSA) were per-
formed according to a previously described method [23].
Briefly, nuclear extracts from liver tissue were prepared,
and then gel shift assays using a NF-kB consensus oligo-
nucleotide (Promega, Madison, WI, USA) were performed.
Samples were separated using 4% polyacrylamide gel
electrophoresis, before the gels were dried and exposed
to radiograph film.Statistical analysis
Statistical analyses were performed using SPSS for Win-
dows, version 12. All results are expressed as the mean ±
SEM. Statistical comparisons were made using the Student
t-test or Scheffe’s method after an analysis of variance. Re-
sults of p < 0.05 were considered statistically significant.Results
iNOS-derived NO promotes liver steatosis in HFD mice
In the NAFLD/HFD model, steatosis was observed after
10 weeks of HFD feed. Typical fibrosis was observed after
36–48 weeks of HFD feed [2,4]. While iNOS−/−/HFD
mice showed microvesicular steatosis, iNOS+/+/HFD
mice showed macrovesicular steatosis in oil-red O staining
liver samples at both 10 and 48 weeks (Figure 1A). Liver
TG content was significantly higher in iNOS+/+/HFD
mice compared with iNOS−/−/HFD mice at both 10
and 48 weeks (Figure 1B). The steatosis grade using NAS
scores showed a tendency for iNOS+/+/HFD mice to be
higher than iNOS−/−/HFD mice at both periods, but not
significantly (Table 2). The results suggested that iNOS-





































Figure 1 Analysis of liver steatosis. (A) Oil-red O staining (red color) shows lipid deposits in liver samples. At both 10 and 48 weeks, macrovesicular
steatosis was visible in iNOS+/+/HFD mice and microvesicular steatosis was visible in iNOS−/−/HFD mice. Scale bar, 200 μm. (B) Liver TG content was
significantly higher in iNOS+/+/HFD mice than in iNOS−/−/HFD mice at both 10 and 48 weeks. (Data are expressed as the mean ± SEM. *p < 0.05,
represents significant difference between iNOS+/+/HFD mice and iNOS−/−/HFD mice).
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fibrosis in 48-week HFD mice
In the 48-week HFD mice groups, analysis of liver in-
flammation using H&E staining revealed histological
inflammation scores which were significantly higher in
iNOS−/−/HFD mice compared with iNOS+/+/HFD
(Table 2, Figure 2A). Serum ALT values were also signifi-
cantly higher in iNOS−/−/HFD mice compared with
iNOS+/+/HFD mice (Figure 2B).
Analysis of liver fibrosis from liver samples subject to
Masson’s trichrome staining using the Brunt classification
revealed that the histological scores and the liver collagen
content (which represent liver fibrosis) were signifi-
cantly higher in iNOS−/−/HFD mice compared with
iNOS+/+/HFD mice after 48 weeks of HFD feed (Table 2,
Figure 2C and D). In contrast, both the iNOS+/+/HFD
and the iNOS−/−/HFD mice showed little or no liver
inflammation or fibrosis after 10 weeks of HFD feed.
(Table 2, Figure 2A and C).Comparison of parameters associated with pathogenesis
of NAFLD between wild-type and iNOS knockout mice in
HFD conditions
Body weights of HFD mice increased during the experi-
mental period, but no significant differences between
iNOS+/+/HFD and iNOS−/−/HFD mice were observed
(Figure 3A). Analysis of several parameters associated
with the pathogenesis of NAFLD revealed that the liver
weights were higher in iNOS+/+/HFD mice compared
with iNOS−/−/HFD mice at 10 weeks; and that serum
adiponectin, leptin and NEFA levels were significantly higher
in iNOS−/−/HFD mice compared with iNOS+/+/HFD mice
at 48 weeks. Liver NEFA content was significantly higher
in iNOS−/−/HFD mice than in iNOS+/+/HFD mice at
48 weeks. No significant difference showed at 10 weeks
(Table 3).
Analysis of systemic IR revealed that the fasting glucose
and fasting insulin levels were significantly higher in
iNOS+/+/HFD mice compared with iNOS−/−/HFD mice
Table 2 Histological scores of livers by using NAFLD activity score (NAS) 17)
10 W model 48 W model
Item Definition Score iNOS+/+ iNOS−/− iNOS+/+ iNOS−/− iNOS+/+ iNOS−/− iNOS+/+ iNOS−/−




<5% 0 6 6 0 0 6 6 0 0
5-33% 1 0 0 4 6 0 0 3 6
33-66% 2 0 0 2 0 0 0 3 0
>66% 3 0 0 0 0 0 0 0 0
Average 0.00 0.00 1.33 1.00 0.00 0.00 1.50 1.00
Inflammation
Lobular inflammation Assessment of all
inflammatory foci
No foci 0 6 6 5 4 6 6 0 0
<2 foci per 200 × field 1 0 0 1 3 0 0 5 2
2-4 foci per 200 × field 2 0 0 0 0 0 0 1 4
>4foci per 200 × field 3 0 0 0 0 0 0 0 0
Liver cell injury Ballooning
None 0 6 6 0 0 6 6 0 0
Few balloon cells 1 0 0 6 6 0 0 4 0
Many cells/prominent
balloooning
2 0 0 0 0 0 0 2 6
Average 0.00 0.00 1.17 1.33 0.00 0.00 2.50* 3.67*
Fibrosis
Stage Method of Brunt
None 0 6 6 6 6 6 6 0 0
Perivenular/perisinusoidal
fibrosis
1 0 0 0 0 0 0 6 0
Combine pericellular
portal fibrosis
2 0 0 0 0 0 0 0 5
Septal/bridging fibrosis 3 0 0 0 0 0 0 0 1
Cirrhosis 4 0 0 0 0 0 0 0 0
Average 0.00 0.00 0.00 0.00 0.00 0.00 1.00** 2.17**
BD, basal diet; HFD, high fat diet;
Significant differences exist between iNOS+/+/HFD vs iNOS−/−/HFD for listed parameters at *p < .05 level and **p < .01 level.
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in iNOS+/+/HFD mice compared with iNOS−/−/HFD
mice at both 10 and 48 weeks (Figure 3B, C and D).
The ITT results at 10 weeks showed that the systemic
response to insulin injection was significantly lower in
iNOS+/+/HFD mice compared with iNOS−/−/HFD mice
(Figure 3E).
Liver nitrate/nitrite concentrations were signifi-
cantly higher in iNOS+/+/HFD mice compared with
iNOS−/−/HFD mice. Interestingly, the increased liver
NO generation was time-dependent and HFD-induced
phenomena. In addition, the increased NO generation
during HFD conditions is considered to be derived fromiNOS, because the iNOS knockout mice did not show an
increase in NO metabolites during HFD conditions. The
liver nitrate/nitrite concentrations in iNOS+/+/HFD mice
were higher at 48 weeks than at 10 weeks (Figure 3F).
Analysis of the mechanisms of liver steatosis,
inflammation and fibrosis
At 48 weeks, it was observed that all sterol regulatory
element binding protein-1c (SREBP-1c), carbohydrate re-
sponse element binding protein (ChREBP), diacylglycerol
acyltransferase2 (DGAT2), PPAR-α1 and MTP were sig-
nificantly down-regulated by the HFD fed mice. Fur-
























































Figure 2 (See legend on next page.)
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Figure 2 Analysis of liver inflammation and liver fibrosis. (A) Liver samples were stained with H&E. By evaluating the amount of inflammatory foci
per field and ballooning, iNOS−/−/HFD mice showed more severe liver inflammation than iNOS+/+/HFD mice at 48 weeks. Scale bar, 200 μm.
(B) Serum ALT levels were significantly higher in iNOS−/−/HFD mice than in iNOS+/+/HFD mice at 48 weeks. (C) Liver samples were stained
with Masson’s trichrome. No obvious fibrosis is visible in the liver specimens from any group at 10 weeks. While only perivenular and perisinusoidal
fibrosis was visible in iNOS+/+/HFD mice, combined pericellular portal fibrosis and bridging fibrosis was visible in iNOS−/−/HFD mice at 48 weeks.
Scale bar, 200 μm. (D) Liver collagen content was significantly higher in iNOS−/−/HFD mice than in iNOS+/+/HFD mice at 48 weeks. (Data are
expressed as the mean ± SEM. * p < 0.05 and ** p < 0.01, represents significant difference between iNOS+/+/HFD mice and iNOS−/−/HFD mice).
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the iNOS+/+/HFD mice (Figure 4A). Analysis of liver
MTP activity was consistent with the results of liver
mRNA expression levels (Figure 4B).
Activated hepatic stellate cells (HSCs) were immuno-
histochemically stained with α-SMA antibodies of only
iNOS−/−/HFD mice at 48 weeks (Figure 5A). Analysis of
liver mRNA involved in activated HSCs promoting liver
fibrosis revealed that liver interleukin1 (IL-1), tumor
necrosis factor-alpha (TNF-α), transforming growth
factor-beta (TGF-β), platelet-derived growth factor (PDGF),
tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2 and
collagen I were significantly up-regulated in iNOS−/−/HFD
mice compared with iNOS+/+/HFD mice (Figure 5B).
As the up-regulated molecules are closely involved with
inflammation and fibrosis, we therefore investigated
their upstream transcriptional regulation. The activa-
tion of NF-kB in iNOS−/−/HFD in comparison to that
in iNOS+/+/HFD mice was observed by EMSA analysis
at 48 weeks (Figure 5C). The increased activation of
NF-kB in hepatic nonparenchymal cells and injured he-
patocytes in iNOS−/−/HFD mice, compared with that in
iNOS+/+/HFD mice, was also confirmed using immuno-
histochemical staining (Figure 5D). To investigate the
localization of NF-kB activation in the liver, we performed
immunohistochemical staining with anti-phospho-NF-kB
and anti-F4/80 antibodies as markers for macrophage
and Kupffer cell lineages and anti-desmin antibodies
as a marker for hepatic stellate cells in iNOS+/+/HFD
and iNOS−/−/HFD mice. Confocal microscopic images
showed that the NF-kB-activated cells were almost
completely merged with the F4/80-positive cells only
in the iNOS−/−/HFD mice (Figure 5E), although the
NF-kB-activated cells were not merged with the desmin-
positive cells in either group of mice (data not shown).
Discussion
NAFLD is a common chronic liver disease displaying a
wide spectrum of liver damage, ranging from simple stea-
tosis to steatohepatitis, advanced fibrosis and cirrhosis. In
the present study, we performed a follow-up study using
HFD-induced NAFLD mouse models with or without
the iNOS gene. Actually, we have previously reported
that genetic variations in iNOS may influence the risk
of NAFLD and liver fibrosis in NAFLD patients [24].In our NAFLD model using HFD conditions, steatosis
was observed after 10 weeks, and typical fibrosis was ob-
served after 36–48 weeks of HFD feed [2,4].
In this study, systemic deficiency of iNOS showed the
drastic promotion of hepatic fibrosis and inflammation
(characteristics of NASH) after 48 weeks of HFD feed.
However, the accumulation of lipids in iNOS-deficient
mice livers after 48 weeks of HFD feed was less than that
in wild-type mice livers. These results indicate that iNOS-
derived NO in HFD conditions prevent hepatic fibrosis
and inflammation, and the deficiency of iNOS strongly ac-
celerates progression to NASH, independent of excessive
lipid accumulation in the liver.
Generally, NO is produced by NOS, an enzyme that
exists in 3 isoforms encoded by distinct genes. While
neural NOS and endothelial NOS are constitutive iso-
forms, iNOS is not expressed under normal conditions
but can be induced by cytokines and lipopolysaccharides
in many cell types, such as hepatocytes, macrophages
(including Kupffer cells), neutrophils, smooth muscle
cells, and chondrocytes [25].
Increased NO generation during HFD conditions in our
study is considered to be derived from iNOS, because
iNOS knockout mice did not show any increase in NO
metabolites during HFD conditions. Additionally, in-
creased NO metabolites in liver is considered to be pro-
duced in liver, because the short half-time of NO in
blood limits the transport of NO to distance tissues and
the actions of NO are restricted to the site of produc-
tion [26]. The up-regulation of iNOS was induced dur-
ing HFD conditions, although the mechanisms involved
in the up-regulation of iNOS during HFD conditions
are unknown. Potential factors involved in iNOS induc-
tion in muscle and fat of HFD-fed obese mice may be
the pro-inflammatory cytokines or NEFA [6]. Further
investigations will be required to clarify the mechanisms.
Perreault M. et al. has reported that systemic deficiency
of iNOS prevented the development of whole-body IR in
mice fed a HFD [6]. Their observations seem at odds with
the findings in our present study that iNOS-derived NO
prevents NASH progression. However, in our model, the
lipid accumulation in iNOS knockout mice livers was less
than that of wild-type mice livers at 48 weeks during HFD
conditions. Also, during the early stages during HFD con-
ditions (10 weeks), whole-body IR was typically observed














































































































































































Figure 3 (See legend on next page.)
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Figure 3 Analysis of factors associated with the pathogenesis of NAFLD: body weight, systemic insulin resistance and liver NO metabolites.
(A) No significant difference was observed between iNOS+/+/HFD and iNOS−/−/HFD mice throughout the experimental period. (B, C and D) Fasting
glucose and fasting insulin levels were significantly higher in iNOS+/+/HFD mice than in iNOS−/−/HFD mice at 10 weeks. HOMA-IR levels were
significantly higher in iNOS+/+/HFD mice than in iNOS−/−/HFD mice at both 10 and 48 weeks. (E) Decreases in blood glucose were significantly
greater in iNOS+/+/HFD mice than in iNOS−/−/HFD mice at 20, 60, 80 and 100 minutes after insulin injection. (F) The liver nitrate/nitrite concentrations
in iNOS+/+/HFD mice were higher at 48 weeks than at 10 weeks; and other groups showed little concentrations at both 10 and 48 weeks.
Liver nitrate/nitrite concentrations were significantly higher in iNOS+/+/HFD mice than in iNOS−/−/HFD mice at both 10 and 48 weeks. (Data are
expressed as the mean ± SEM. * p < 0.05 and ** p < 0.01, represents significant difference between iNOS+/+/HFD mice and iNOS−/−/HFD mice).
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results similar to those of Perreault. Why was the dis-
crepancy observed? Is iNOS-derived NO good or bad
for the progression to NASH?
Based on the long-term observations (48 weeks), the
deficiency of iNOS-derived NO during HFD conditions
accelerates progression to NASH. In addition, fibrosis and
inflammation were easily induced by a lack of NO, without




Number of animals 6 6 6
Liver weight (g) 1.25 1.12 3.11*
±0.07 ±0.05 ±0.18
Visceral fat weight (g/100 g BW) 2.24 1.98 5.10
±0.15 ±0.17 ±0.32
Subcutaneous fat weight (g/100 g BW) 0.64 0.74 4.22
±0.11 ±0.12 ±0.20
Mesenterial fat weight (g/100 g BW) 0.36 0.57 3.02
±0.03 ±0.08 ±0.19
Serum cholesterol (mg/dL) 86.4 82.6 167.7
±3.6 ±5.7 ±6.5
Serum TG (mg/dL) 30.1 23.8 40.1
±3.1 ±5.0 ±4.5
Serum VLDL-TG (pg/mL) 12.7 11.7 16.4
±4.2 ±1.8 ±2.4
Serum adiponectin (μg/mL) 15.0 15.1 13.3
±1.4 ±1.3 ±0.6
Serum leptin (ng/mL) 2.6 1.4 29.8
±0.5 ±0.4 ±1.0
Serum NEFA (mEq/L) 1.0 0.9 1.5
±0.1 ±0.1 ±0.1
Liver NEFA contents (μEq/g) 13.9 18.3 12.4
±2.5 ±6.0 ±1.4
BD, basal diet; HFD, high fat diet; TG, triglyceride; VLDL-TG, very low density lipopro
NEFA, nonesterified fatty acid
Data are expressed as mean ± SEM.
Significant differences exist between iNOS+/+/HFD vs iNOS−/c/HFD for listed parampathogenesis of our long-term NASH model observations
of iNOS-deficiency during HFD conditions may represent
advanced NASH, while intrahepatic lipogenesis might also
be suppressed. Rockey D.C. et al. suggested that the role of
iNOS during hepatic injury and fibrosis varied with differ-
ences in the type of insult, duration and amount of NO
actually generated in the liver [9]. In our present study,
time-dependent and HFD-induced increases in NO gener-
ation in the liver were observed. Thus, the discrepancy48 W model
+/+ iNOS−/− iNOS+/+ iNOS−/− iNOS+/+ iNOS−/−
HFD BD BD HFD HFD
6 6 6 6 6
2.19* 1.22 1.45 5.92 5.38
±0.32 ±0.24 ±0.11 ±0.61 ±0.38
5.26 2.60 2.77 3.52 3.49
±0.50 ±1.18 ±0.40 ±0.04 ±0.52
3.81 1.17 0.91 4.65 4.91
±0.37 ±0.53 ±0.20 ±0.23 ±0.66
3.09 1.10 0.56 1.39 1.54
±0.14 ±0.91 ±0.04 ±0.07 ±0.02
133.3 88.3 67.7 230.6 283.7
±16.6 ±9.7 ±4.6 ±24.0 ±10.4
35.0 26.8 26.4 16.5 17.5
±1.9 ±3.1 ±1.5 ±0.4 ±2.6
14.7 11.6 14.6 3.5 4.0
±1.2 ±1.3 ±1.6 ±0.1 ±0.6
13.2 11.0 10.7 6.9* 8.5*
±0.7 ±0.7 ±0.3 ±0.4 ±0.1
27.7 3.1 3.2 60.9* 130.7*
±1.1 ±0.6 ±0.5 ±12.1 ±27.4
1.6 0.9 1.3 1.7* 2.6*
±0.1 ±0.2 ±0.2 ±0.1 ±0.2
12.6 10.3 8.4 10.7 17.6*
±1.4 ±1.1 ±0.8 ±1.6 ±2.7
tein-TG;




















































































Figure 4 Analysis of the mechanisms of liver steatosis. (A) Liver SREBP-1c, ChREBP, DGAT2, PPAR-α1 and MTP mRNA expression levels were
all significantly lower in iNOS−/−/HFD mice than in iNOS+/+/HFD mice at 48 weeks. (B) Liver MTP activity was significantly lower in iNOS−/−/HFD
mice than in iNOS+/+/HFD mice at 48 weeks. (Data are expressed as the mean ± SEM. * p < 0.05, represents significant difference between
iNOS+/+/HFD mice and iNOS−/−/HFD mice).
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ence in duration and the amount of NO [9,27], in the
same way that the conflicting effects of NO on the
NAFLD/NASH liver [12,13] have been explained.
In an advanced-NASH mouse model at 48 weeks under
HFD conditions, the high dose and long duration of the
NO levels had a protective effect against hepatic inflam-
mation and fibrosis. The reason why the iNOS-knockout
mice fed an HFD had severer liver fibrosis despite the fact
that they had less-severe hepatic steatosis may be an in-
crease in serum NEFA and the liver NEFA content as a
result of interactions among NO metabolites. Yamaguchi
et al. and Soufi et al. reported that the accumulation of
TG may be a protective mechanism preventing the pro-
gression of NAFLD/NASH and suggested that free fatty
acid is a pathogenic mediator in the development of
NASH, based on the progression of liver damage that
occurs despite striking improvements in systemic insu-
lin resistance and hepatic TG content [28,29].
The present study demonstrated that liver SREBP-1c,
ChREBP, DGAT2, PPAR-α1 and MTP mRNA expression
levels were all significantly decreased in iNOS-knockout
mice fed an HFD for 48 weeks and that exhibited theprogression of liver fibrosis, consistent with previous study
results showing that the hepatic expression levels of genes
involved in lipogenesis, fatty acid catabolism, and VLDL
export in the liver were all suppressed during NASH
pathogenesis [30]. In our study, a reduction in fat droplets
in the liver during the unbalanced synthesis and discharge
of lipids (“burned-out NASH”) might have occurred in the
iNOS-deficient mouse at 48 weeks under HFD conditions.
In both the early-NASH mouse model at 10 weeks and
the advanced-NASH mouse model at 48 weeks under
HFD conditions, the long duration of the NO levels as-
sociated with either dose had an accelerative effect on
systemic insulin resistance, although the NO conditions
did not affect the local intrahepatic insulin resistance.
Yamaguchi et al. reported a discrepancy between the pro-
gression of liver fibrosis and the striking improvement in
systemic insulin resistance in mice fed a methionine and
choline diet that were treated with DGAT2 antisense
oligonucleotide; however, a detailed mechanism is not
obvious [28].
The ob/ob mice lacking iNOS showed an improve-
ment in energy balance because of a decrease in food
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Figure 5 (See legend on next page.)
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Figure 5 Analysis of the mechanisms of liver inflammation and liver fibrosis, and of the effects of NF-kB activity inhibitor on iNOS
knockout/HFD mice livers at 48 weeks. (A) Liver samples were stained with α-SMA antibodies. Pericellular staining was visible only in
iNOS−/−/HFD mice at 48 weeks. Scale bar, 50 μm. (B) Liver IL-1, TGF-β, PDGF, TIMP-1, TIMP-2 and collagen I mRNA expression levels were
significantly higher in iNOS−/−/HFD mice than in iNOS+/+/HFD mice at 48 weeks. (C) Analysis of liver NF-kB activity by EMSA showed that
the NF-kB band of iNOS−/−/HFD mice at 48 weeks was enhanced compared with iNOS+/+/HFD mice. P.C.: positive control using HeLa
cells. N.C.: negative control. (D) NF-kB protein was expressed in the nucleus of hepatic nonparenchymal cells and injured hepatocytes in
iNOS−/−/HFD mice at 48 weeks. (E) Confocal microscopic images showed that NF-kB-activated cells (red) were almost completely merged
with F4/80-positive cells (green) in iNOS−/−/HFD mice. The nuclei were stained with 4′-diamidine-2′-phenylindole hydrocholoride (DAPI: blue). (Data
are expressed as the mean ± SEM. * p < 0.05, represents significant difference between iNOS+/+/HFD mice and iNOS−/−/HFD mice).
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ments [31].
To clarify the mechanisms of hepatic fibrosis and in-
flammation induced by iNOS-derived NO deficiency
during HFD conditions, we hypothesized that activation
of NF-kB, which controls transcription of various pro-
inflammatory genes, including cytokines, might be pro-
moted by the iNOS deficiency. Our data showed an increase
in expression levels of various cytokines that are transcrip-
tionally controlled by NF-kB in the iNOS-deficient mouse
liver. Liver NF-kB activity has previously been shown to
be correlated with the pathogenesis of NASH [32], and
biphasically regulated by NO [27]. The NO mechanism
involved to bring about biphasic regulation of NF-kB ac-
tivity is currently under investigation. NO induces and
stabilizes the inhibitor of kappaBα (IkBα), which prevents
nuclear location of NF-kB [33]. Connelly et al. reported














Figure 6 Scheme. iNOS-derived NO may play a protective role against the
and inflammation mediated by NF-kB activation in Kupffer cells.influence on NF-kB activity and that NF-kB was enhanced
at certain concentrations of NO followed by inhibition at
a higher concentration [27]. Our EMSA results showed
that the activation of liver NF-kB was significantly en-
hanced by the deficiency of iNOS-derived NO in the liver
during HFD conditions, and confocal microscopic images
showed that NF-kB-activated cells were almost consistent
with the location of Kupffer cells. Therefore, in our NASH
model, increased liver NO concentrations of wild-type
mice might inhibit NF-kB activity in Kupffer cells. In con-
trast, iNOS deficiency under the same conditions might
activate NF-kB in Kupffer cells, compared with the situ-
ation in wild-type mice. Further investigation is required
to determine whether the activation of NF-kB in Kupffer
cells might be one of the mechanisms involved in the pro-
gression of hepatic inflammation.
The main limitations of this study are related to its
long-term study design and its inability to excludelation
mation  
protection against fibrosis and inflammation
 fibrosis and inflammation
ation
Kupffer cells
progression to NASH under HFD conditions by preventing fibrosis
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changes in liver diseases have been previously reported
with or without iNOS [34-36]. Aging may be a risk
factor for metabolic syndrome and diet-induced stea-
tohepatitis and might be accompanied by an increase
in iNOS expression, consistent with our results shown
in Figure 3F.
Conclusions
In conclusion, iNOS-derived NO may play a protective
role against the progression to NASH under HFD condi-
tions by preventing fibrosis and inflammation mediated
by NF-kB activation in Kupffer cells. A lack of iNOS-
derived NO accelerates progression to NASH, without
excessive lipid accumulation, despite promoting systemic
IR in the chronic NASH experimental model induced by
long-term HFD feeding (Figure 6).
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